Raz I - Search Results

1

Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel.

Consoli A, Czupryniak L, Duarte R, Jermendy G, Kautzky-Willer A, Mathieu C, Melo M, Mosenzon O, Nobels F, Papanas N, Roman G, Schnell O, Sotiropoulos A, Stehouwer CDA, Tack CJ, Woo V, Fadini GP, Raz I. Consoli A, et al. Among authors: raz i. Diabetes Obes Metab. 2020 Oct;22(10):1705-1713. doi: 10.1111/dom.14102. Epub 2020 Jul 5. Diabetes Obes Metab. 2020. PMID: 32476244 Review.

2

Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial.

Raz I, Avron A, Tamir M, Metzger M, Symer L, Eldor R, Cohen IR, Elias D. Raz I, et al. Diabetes Metab Res Rev. 2007 May;23(4):292-8. doi: 10.1002/dmrr.712. Diabetes Metab Res Rev. 2007. PMID: 17124720 Clinical Trial.

3

Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women.

Szalat A, Raz I. Szalat A, et al. Among authors: raz i. Diabetes Obes Metab. 2008 Dec;10(12):1135-56. doi: 10.1111/j.1463-1326.2008.00896.x. Epub 2008 May 20. Diabetes Obes Metab. 2008. PMID: 18494812 Review.

4

Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial.

Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, Jermendy G, Campaigne BN, Kerr L, Milicevic Z, Jacober SJ. Raz I, et al. Diabetes Care. 2009 Mar;32(3):381-6. doi: 10.2337/dc08-1671. Diabetes Care. 2009. PMID: 19246588 Free PMC article. Clinical Trial.

5

C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory study.

Buzzetti R, Cernea S, Petrone A, Capizzi M, Spoletini M, Zampetti S, Guglielmi C, Venditti C, Pozzilli P; DiaPep Trialists Group. Buzzetti R, et al. Diabetes. 2011 Nov;60(11):3067-72. doi: 10.2337/db10-0560. Epub 2011 Sep 6. Diabetes. 2011. PMID: 21896927 Free PMC article. Clinical Trial.

6

Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms.

Raz I, Eldor R. Raz I, et al. Diabetes Metab Res Rev. 2012 May;28(4):321-4. doi: 10.1002/dmrr.2265. Diabetes Metab Res Rev. 2012. PMID: 22173845

7

Diabetes therapy--focus on Asia: second-line therapy debate: insulin/secretagogues.

Eldor R, Raz I. Eldor R, et al. Among authors: raz i. Diabetes Metab Res Rev. 2012 Dec;28 Suppl 2:85-9. doi: 10.1002/dmrr.2358. Diabetes Metab Res Rev. 2012. PMID: 23280872 Review.

8

Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.

Mosenzon O, Raz I, Scirica BM, Hirshberg B, Stahre CI, Steg PG, Davidson J, Ohman P, Price DL, Frederich B, Udell JA, Braunwald E, Bhatt DL. Mosenzon O, et al. Among authors: raz i. Diabetes Metab Res Rev. 2013 Jul;29(5):417-26. doi: 10.1002/dmrr.2413. Epub 2013 May 21. Diabetes Metab Res Rev. 2013. PMID: 23564755 Clinical Trial.

9

Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum.

Raz I, Riddle MC, Rosenstock J, Buse JB, Inzucchi SE, Home PD, Del Prato S, Ferrannini E, Chan JC, Leiter LA, Leroith D, Defronzo R, Cefalu WT. Raz I, et al. Diabetes Care. 2013 Jun;36(6):1779-88. doi: 10.2337/dc13-0512. Diabetes Care. 2013. PMID: 23704680 Free PMC article.

10

Emerging gliptins for type 2 diabetes.

Cahn A, Raz I. Cahn A, et al. Among authors: raz i. Expert Opin Emerg Drugs. 2013 Jun;18(2):245-58. doi: 10.1517/14728214.2013.807796. Expert Opin Emerg Drugs. 2013. PMID: 23725569 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

472 results

Search Page